Strategic Collaborations Attracting Biopharmaceuticals Manufacturers for Business Expansion


Published Date : Dec 16, 2015

The global biopharmaceuticals market has been posting an impressive growth since past few years. The high efficiency with minimal side-effects of biopharmaceutical drugs has boosted their popularity across the globe, grabbing the attention of major players operating in the pharmaceutical industry. At present, the market is heavily stimulated by the rising investment for R&D activities as well as rapid technical advancements in biopharmaceuticals. Partnership and alliances is the latest trend among market players, looking to enhance their product portfolio.

Novartis, one of the world’s biggest pharmaceutical company, has associated with NeoBiocon for the commercial production of Jalra (Vildagliptin) as well as Jalra-M (Vildagliptin Metformin) in the UAE. NeoBiocon, which is a joint venture of Asia’s leading biopharma company, Biocon, and UAE-based Neopharma, is likely to benefit in the diabetics and the metabolics segments in the UAE biopharma market from this collaboration.

Akebia Therapeutics, an international biopharmaceutical enterprise, has recently joined hands with Mitsubishi Tanabe Pharma Corp. for the development of vadadustat (formerly AKB-6548), an oral drug for the treatment of chronic kidney disease-related anemia. The companies have plans for the commercialization of this drug in Japan and several other Asian countries.

Biogen, another major biopharma drugmaker, has entered into a collaborative agreement with Arsia Therapeutics, a U.K.-based enterprise, aimed at providing advanced treatment to hemophilia patients to transform their experience. As per the agreement, Biogen is also allowed to use the patented formulation technology of Arsia, which owns a broad-based facility for the manufacturing of high-concentration medical dose of protein and antibody drugs, significant for next-generation biologics.

GE Healthcare Life Sciences has partnered with Emerson Electric Co. in a bid to increases its efficiency for the production of biopharmaceutical products. According to the agreement, Emerson will be integrating its DeltaV-distributed control system with the highly advanced comprehensive technologies of GE Healthcare for the development of monoclonal antibodies and vaccines. This collaboration sets a perfect example amidst heavy demand for such processes by biopharmaceutical drugmakers.

Other major collaboration recently happened in the global biopharmaceuticals market are Rhizen Pharmaceuticals entering into a worldwide licensing agreement with Novartis and Eiger BioPharmaceuticals acquiring Celladon Corp.